Undisclosed BCMA CAR-NK
/ Pregene Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 29, 2023
Single VHH-directed BCMA CAR-NK cells for multiple myeloma.
(PubMed, Exp Hematol Oncol)
- "In the MM.1S-Luc mouse model, BCMA-CD28-IL15 CAR-NK inhibited the growth of tumor cells and prolonged mouse survival. These results show that the single VHH-directed BCMA CAR-NK cells exhibited remarkable specific killing ability, making them a potential candidate for immunotherapy in multiple myeloma treatment."
IO biomarker • Journal • Hematological Malignancies • Multiple Myeloma • Oncology • IL15
December 15, 2022
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
(clinicaltrials.gov)
- P1 | N=19 | Recruiting | Sponsor: Shenzhen Pregene Biopharma Co., Ltd.
IO biomarker • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 2
Of
2
Go to page
1